Effectiveness of Vitamin D augmentation to Sertraline in treatment of Anxiety Disorders - NI

Government Medical College and Hospital0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年6月24日

试验速览

暂无简介。

•1.Patients with a primary diagnosis of Anxiety or fear related disorders as per ICD-11
•(which includes patients diagnosed with Generalized Anxiety Disorder, Panic Disorder,
•Agoraphobia, Specific Phobia, Social Anxiety Disorder, Separation Anxiety Disorder,
•Selective Mutism, Other Specified Anxiety or Fear-Related Disorders).
•2.Age group of 18-65yrs.
•3.Any gender.
•4.Vitamin D levels between 30nmol/L-75nmol/L.
•5.Not on any psychotropic medication for current episode of illness
•6.Patients having the capacity to give informed written consent as per section 4 of MHCA,

•1. Patients with an active substance use disorder within the past 6 months(in terms of
•fulfilling the ICD-11 criteria for substance dependence) except caffeine and nicotine.
•2. Patients with any acute medical or surgical illness, anaemia, thyroid disoders.
•3. Pregnant and lactating females.
•4. Acutely violent patients or those having a current serious suicide risk.
•5. Taking vitamins or dietary supplements containing vitamin D in last 3 months.
•6. History of treatment resistance/poor response or major side-effects with SSRIs.
•7. Having co-morbid diagnosis of intellectua ldisability, dementia, Alzeihmers disease,
•Parkinsons disease, Epilepsy.
•8. Other co-morbid psychiatric illnesses including Schizophrenia, mood disorders,
•Obsessive compulsive and related disorder, disorders associated with stress (including
•PTSD and adjustment disorders), sleep disorders, eating disoders.

发起方

Government Medical College and Hospital